{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-023210","form_type":"8-K","ticker":"CTMX","cik":"0001501989","company_name":"CytomX Therapeutics, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.888937+00:00","generated_at":"2026-06-22T03:27:18.071150+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CytomX Q3 cash falls to $194.3M; revenue $16.9M; restructuring $7.1M; IND targets set for 2023","bullets":["Cash and investments $194.3M as of Sep 30, 2022, down from $305.2M at Dec 31, 2021.","Revenue $16.9M for Q3 2022 vs $17.6M for Q3 2021, down ~4%.","R&D expense $30.4M, G&A $10.5M; restructuring charges $7.1M in Q3.","IND for CX-2051 and CX-801 expected H2 2023; CX-2029 sqNSCLC data update Q4 2022.","Company restructuring announced July 2022 to be completed by end of 2022; total ~$7.9M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-023210","json":"https://secwatch.observer/filing/0000950170-22-023210.json","markdown":"https://secwatch.observer/filing/0000950170-22-023210.md","text":"https://secwatch.observer/filing/0000950170-22-023210.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501989/000095017022023210/0000950170-22-023210-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501989/000095017022023210/ctmx-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:27:18.071150+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1bf2bf26289f3f8ef14ba699bec21b6d6e785530","claim":"CytomX Therapeutics, Inc. reported financial results for for the three months and nine months ended September 30, 2022.","evidence_excerpt":"On November 8, 2022, CytomX Therapeutics, Inc., a Delaware corporation (the “Company”) issued a press release reporting its unaudited financial results as of and for the three months and nine months ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501989/000095017022023210/0000950170-22-023210-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the three months and nine months ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}